These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 15863556)

  • 1. 17 hydroxyprogesterone for the prevention of preterm delivery.
    Meis PJ;
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
    Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F; Vaccaro V
    Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
    Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From concept to practice: the recent history of preterm delivery prevention. Part II: Subclinical infection and hormonal effects.
    Vidaeff AC; Ramin SM
    Am J Perinatol; 2006 Feb; 23(2):75-84. PubMed ID: 16506112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.
    Rebarber A; Istwan NB; Russo-Stieglitz K; Cleary-Goldman J; Rhea DJ; Stanziano GJ; Saltzman DH
    Diabetes Care; 2007 Sep; 30(9):2277-80. PubMed ID: 17563346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Rozenberg P; Chauveaud A; Deruelle P; Capelle M; Winer N; Desbrière R; Perrotin F; Bohec C; Connan L; Vayssière C; Langer B; Mantel A; Azimi S; Porcher R; Azria E;
    Am J Obstet Gynecol; 2012 Mar; 206(3):206.e1-9. PubMed ID: 22381603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
    Rittenberg C; Newman RB; Istwan NB; Rhea DJ; Stanziano GJ
    J Reprod Med; 2009 Feb; 54(2):47-52. PubMed ID: 19301566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
    Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
    Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
    Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery.
    Sibai B; Meis PJ; Klebanoff M; Dombrowski MP; Weiner SJ; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1181-6. PubMed ID: 16157134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
    Rebarber A; Ferrara LA; Hanley ML; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
    Am J Obstet Gynecol; 2007 Mar; 196(3):224.e1-4. PubMed ID: 17346529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study.
    Shennan A; Crawshaw S; Briley A; Hawken J; Seed P; Jones G; Poston L
    BJOG; 2006 Jan; 113(1):65-74. PubMed ID: 16398774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
    Gupta S; Roman AS
    Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial.
    DeFranco EA; O'Brien JM; Adair CD; Lewis DF; Hall DR; Fusey S; Soma-Pillay P; Porter K; How H; Schakis R; Eller D; Trivedi Y; Vanburen G; Khandelwal M; Trofatter K; Vidyadhari D; Vijayaraghavan J; Weeks J; Dattel B; Newton E; Chazotte C; Valenzuela G; Calda P; Bsharat M; Creasy GW
    Ultrasound Obstet Gynecol; 2007 Oct; 30(5):697-705. PubMed ID: 17899571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
    Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
    Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
    How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
    Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.